Santiago Moreno

Santiago Moreno is a seasoned HEOR/HTA professional with over 14 years of experience in the industry and public sector. He has held key positions at reputable organizations such as Novartis and Roche.

Currently, Santiago spearheads the Global HEOR strategy for Novartis' Cosentyx®, focusing on market and pipeline indications in rheumatology & dermatology. His role involves ensuring the evidence package aligns with pricing and reimbursement negotiations, emphasizing PRO value claims on regulatory labels.

Santiago's accomplishments include leading Novartis' first submission to EUnetHTA for Rydapt® and contributing to policy proposals in HTA/payer discussions. He holds a Ph.D. in Medical Statistics from the UK and has a strong educational background in biopharmaceutical pricing, market access strategy, and business mathematics.

With a career spanning various roles such as Health Economist, HEOR Director, and Global Health Economist, Santiago's expertise encompasses evidence synthesis methodology for comparative effectiveness, solidifying his reputation in the field.